日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

一项 I 期研究，旨在评估 PF-06939999（PRMT5 抑制剂）在具有高发剪接因子基因突变的特定晚期或转移性肿瘤患者中的安全性、药代动力学和药效学。

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.102961
Rodon, J; Rodriguez, E; Maitland, M L; Tsai, F Y-C; Socinski, M A; Berlin, J D; Thomas, J S; Al Baghdadi, T; Wang, I-M; Guo, C; Golmakani, M; Clark, L N; Gazdoiu, M; Li, M; Tolcher, A W
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

预测晚期鳞状细胞肺癌对EGFR靶向单克隆抗体反应的生物标志物

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdy196
Bonomi, P D; Gandara, D; Hirsch, F R; Kerr, K M; Obasaju, C; Paz-Ares, L; Bellomo, C; Bradley, J D; Bunn, P A Jr; Culligan, M; Jett, J R; Kim, E S; Langer, C J; Natale, R B; Novello, S; Pérol, M; Ramalingam, S S; Reck, M; Reynolds, C H; Smit, E F; Socinski, M A; Spigel, D R; Vansteenkiste, J F; Wakelee, H; Thatcher, N
单克隆抗体
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2018
文献求助 收藏

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

SQUIRE研究中EGFR表达与安全性和疗效结果的相关性：一项随机、多中心、开放标签的III期研究，比较吉西他滨-顺铂联合奈西妥单抗与吉西他滨-顺铂单药一线治疗IV期鳞状非小细胞肺癌患者的疗效

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw214
Paz-Ares, L; Socinski, M A; Shahidi, J; Hozak, R R; Soldatenkova, V; Kurek, R; Varella-Garcia, M; Thatcher, N; Hirsch, F R
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2016
文献求助 收藏

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy

PD-L1检测在选择适合接受PD-1/PD-L1靶向治疗的非小细胞肺癌患者中的临床应用价值

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.385
Villaruz, L C; Socinski, M A
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
PD-1
发表日期：2016
文献求助 收藏

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

紫杉烷类药物一线治疗晚期非小细胞肺癌的最新进展

期刊:Current Oncology
影响因子:3.4
doi:10.3747/co.21.1997
Socinski, M A
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

一项随机、双盲、II 期研究，评估厄洛替尼联合或不联合舒尼替尼作为转移性非小细胞肺癌 (NSCLC) 二线治疗的疗效

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdt212
Groen H J M, Socinski M A, Grossi F, Juhasz E, Gridelli C, Baas P, Butts C A, Chmielowska E, Usari T, Selaru P, Harmon C, Williams J A, Gao F, Tye L, Chao R C, Blumenschein G R Jr
细胞生物学
肺癌
发表日期：2013
文献求助 收藏